A Phase 2 interventional study of Pomalidomide and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Completed at 22 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-27.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.
Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 32nd largest by enrollment, is one of 11 that started in 2014, is one of 55 in phase 2, and was the 27th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Shandong New Time Pharmaceutical Co., LTD · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Celgene · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 75 · Phase 3 17 · Phase 4 2
First in 2007; this study’s year is marked. 11 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 102 interventional studies. Of the 48 that completed or were terminated, 24 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 102 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 56th largest by enrollment of the 108 interventional ones that give a count, is one of 11 that started in 2014, is one of 24 in phase 2, and was the 64th registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
10 of the studies testing pomalidomide in Multiple Myeloma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
| NCT04508790City of Hope Medical CenterLeflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2027-02-14 |
Add all 10 to your calendar (.ics) → With an account.
Among the 102 studies testing pomalidomide in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple myeloma, with moderate or severe renal impairment.
The study will consist of a Screening phase within 28 days prior to cycle 1 day 1. Subjects once enrolled will enter the Treatment phase, in which patients will be treated until progression, or study discontinuation due to other reasons. Subjects will enter the long term Follow-up phase of the study where data will be collected every 3 months for up to 5 years on Secondary primary malignancies, survival, subsequent anti myeloma treatments and date of progression. Subjects will be recruited into one of 3 cohorts depending on the severity of their renal impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment
Prior history of , other than MM, unless the subject has been free of the disease for ≥ 5 years; exceptions include the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (\> 75 years old)
Drug: Pomalidomide and Dexamethasone
Drug pages: Pomalidomide · Dexamethasone
Also known as: Tablet
Evaluate efficacy of the combination of pomalidomide and low-dose dexamethasone in subjects with RRMM and impaired renal function
Overall response rate determined by Myeloma responses determined by modified IMWG criteria
Time frame: Approximately 2 years
Assessment of renal response according to the criteria defined by Dimopoulos and Ludwig (Dimopoulos, 2009; Dimopoulos, 2010 b,c; Ludwig, 2010).
Assessment of renal response according to the criteria defined by Ludwig and Dimopoulos
Time frame: Approximately 2 years
Time to Myeloma response
Evaluated according to the CTCAE grading
Time frame: Approximately 2 years
Time to renal response
Evaluated according to the CTCAE grading
Time frame: Approximately 2 years
Duration of response
Evaluated according to the CTCAE grading
Time frame: Approximately 2 years
Progression-free survival
Evaluated according to the CTCAE grading
Time frame: Approximately 2 years
Time to progression
Evaluated according to the CTCAE grading
Time frame: Approximately 2 years
Overall Survival
Evaluated according to the CTCAE grading
Time frame: Approximately 2 years
Adverse events (AEs) assessment (type, frequency, seriousness, severity, relationship to pomalidomide and/or dexamethasone and outcomes) including second primary malignancy (SPM).
Pharmacokinetics (PK) of pomalidomide in subjects with RRMM and impaired renal function (moderate to severe renal impairment).
Time frame: Approximately 2 years
Ran from Feb 2014 to primary completion in Jan 2017, 34 months.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 34 months is below that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pomalidomide · Dexamethasone